Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Equity Average (2019 - 2025)

Allogene Therapeutics' Equity Average history spans 7 years, with the latest figure at $329.9 million for Q3 2025.

  • For Q3 2025, Equity Average fell 32.58% year-over-year to $329.9 million; the TTM value through Sep 2025 reached $329.9 million, down 32.58%, while the annual FY2024 figure was $467.2 million, 20.75% down from the prior year.
  • Equity Average for Q3 2025 was $329.9 million at Allogene Therapeutics, down from $365.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.0 billion in Q2 2021 and bottomed at $329.9 million in Q3 2025.
  • The 5-year median for Equity Average is $606.7 million (2023), against an average of $664.2 million.
  • The largest annual shift saw Equity Average surged 68.61% in 2021 before it plummeted 32.58% in 2025.
  • A 5-year view of Equity Average shows it stood at $947.6 million in 2021, then fell by 25.58% to $705.1 million in 2022, then decreased by 22.51% to $546.4 million in 2023, then decreased by 18.94% to $443.0 million in 2024, then dropped by 25.51% to $329.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Equity Average are $329.9 million (Q3 2025), $365.0 million (Q2 2025), and $403.8 million (Q1 2025).